<\/p>\n
December 4, 2024 \u2013 release at 7:30 am CET<\/strong> Nicox SA<\/strong> (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the first commercial sale of ZERVIATE\u00ae (cetirizine ophthalmic solution), 0.24% in China by its exclusive Chinese partner Ocumension Therapeutics. ZERVIATE is indicated for ocular itching associated with allergic conjunctivitis and was approved<\/a> in China in September 2024.<\/p>\n ZERVIATE is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC\u00ae<\/sup>, and is currently commercialized in the U.S. for ocular itching associated with allergic conjunctivitis by Nicox\u2019s exclusive U.S. partner, Harrow, Inc. Ocumension emphasizes that ZERVIATE is suitable for the treatment of allergic conjunctivitis in toddlers and preschoolers, which significantly fills the medical gap in this field and benefits the vast number of children in China.<\/p>\n \u201cThe first commercial sale of ZERVIATE in China by our partner Ocumension, marks the next significant milestone in this broad collaboration initiated in 2018 and provides a new revenue stream for Nicox. Ocumension has proven itself to be a strong development partner through their work on ZERVIATE and on the recruitment of Chinese patients in the NCX 470 Denali Phase 3 study. They have also been building out commercial operations through organic and external growth, including acquiring products and operations from a leading player in China, ideally placing them to maximise the value of ZERVIATE in the Chinese market. We look forward to continuing to work with them as we advance NCX 470 towards commercialisation as well.<\/em>\u201d said Gavin Spencer, Chief Executive Officer of Nicox.<\/strong>\u00a0\u00a0 <\/p>\n ZERVIATE is exclusively licensed to Ocumension for development and commercialization in the Chinese and the majority of the Southeast Asian markets.\u00a0 Nicox may potentially receive sales milestones of up to US$17.2 million together with royalties from 5% to 9% on net sales of ZERVIATE by Ocumension.\u00a0<\/p>\n<\/td>\n<\/div>\n Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. <\/p>\n
Sophia Antipolis, France<\/p>\nNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.\u00a0 Nicox\u2019s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.\u00a0 Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos.\u00a0 Nicox\u2019s first product, VYZULTA\u00ae in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories.\u00a0 Nicox generates revenue from ZERVIATE\u00ae in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.\u00a0\u00a0 <\/p>\n